Edward Nash
Stock Analyst at Canaccord Genuity
(4.18)
# 471
Out of 5,090 analysts
83
Total ratings
56%
Success rate
13.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $591.06 | -0.69% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $38.86 | +175.35% | 2 | Nov 12, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $14 → $16 | $7.99 | +100.25% | 7 | Nov 7, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $73 → $54 | $54.59 | -1.07% | 7 | Oct 9, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $6.37 | +339.56% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $4.13 | +384.26% | 3 | Sep 30, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $140 | $85.15 | +64.42% | 10 | Sep 25, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $29.59 | +109.53% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $35.39 | +32.81% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.58 | +471.43% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.30 | +207.69% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $75.40 | +18.04% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $0.96 | +735.77% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $9.59 | +77.18% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.74 | -27.01% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.14 | +15,689.47% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $36.60 | +124.04% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $4.18 | +1,816.17% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $23.09 | +107.88% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $4.89 | +13,196.24% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $591.06
Upside: -0.69%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $38.86
Upside: +175.35%
Ventyx Biosciences
Nov 7, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $7.99
Upside: +100.25%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $73 → $54
Current: $54.59
Upside: -1.07%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $6.37
Upside: +339.56%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $4.13
Upside: +384.26%
Corcept Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $140
Current: $85.15
Upside: +64.42%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $29.59
Upside: +109.53%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $35.39
Upside: +32.81%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.58
Upside: +471.43%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.30
Upside: +207.69%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $75.40
Upside: +18.04%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $0.96
Upside: +735.77%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $9.59
Upside: +77.18%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.74
Upside: -27.01%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.14
Upside: +15,689.47%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $36.60
Upside: +124.04%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $4.18
Upside: +1,816.17%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $23.09
Upside: +107.88%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $4.89
Upside: +13,196.24%